Watson gains exclusive US rights to HRA Pharma's ulipristal and Abbott makes deal with Fabre for MAb

2 February 2010

US drugmaker Watson Pharmaceuticals entered an exclusive licensing agreement to become the commercial partner for ulipristal acetate (UPA), a selective progesterone receptor modulator in the USA.

UPA is a novel next-generation emergency contraceptive developed by France-headquartered HRA Pharma specifically for emergency contraceptive use that is approved and marketed by the firm in Europe as ellaOne since October 2009. UPA is at the New Drug Application (NDA) stage in the USA.

Under the terms of the licensing agreement, Watson will make payments to HRA Pharma, based on the achievement of certain milestones. In addition, Watson will also pay HRA Pharma a royalty on US sales of the product and will be responsible for all US commercialization and marketing expenses. Further financial details were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK